22nd Century Group (Nasdaq: XXII) has acquired GVB Biopharma. Read the press release
here
Home
About Us
Our Company
Our Leadership Team
Board of Directors
Reduced Nicotine Tobacco
VLN®
Clinical Studies & Commentaries
Hemp/Cannabis Innovation
GVB Biopharma
Hops Research
News
Investors
Overview
New Investor / Latest Resources
Events
News
Stock Data
SEC Filings
Analyst Coverage
Corporate Governance
Annual Reports
FAQs
Contact Us
Sitemap
22nd Century Group, Inc. Sitemap
Home
About Us
Our Company
Leadership Team
Board of Directors
Reduced Nicotine Tobacco
VLN®
Clinical Studies & Commentaries
Clinical Studies on Benefits of Using Reduced Nicotine Content Cigarettes
On-Going Clinical Studies Using Reduced Nicotine Content Cigarettes
Commentaries & Opinion Pieces on Reduced Nicotine Content Cigarettes
Hemp/Cannabis Innovation
GVB Biopharma
Hops Research
News & Media
Investors
Overview
New Investor / Latest Resources
Events
News
Press Releases
Stock Data
Quote
Charts
Historical Data
Trades
SEC Filings
Analyst Coverage
Corporate Governance
Annual Reports
FAQs
Contact Us
Privacy Policy / CCPA
Disclaimer
Sitemap